Affinity DataIC50: 0.300nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated...More data for this Ligand-Target Pair
Affinity DataIC50: 0.400nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated...More data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 0.600nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of human ErbB2More data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 2.10nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 2.90nMAssay Description:Binding affinity to human N-terminal His-tagged cIAP1 BIR2-3 C202A/C213G mutant after 60 mins by HTRF assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of cIAP1 BIR2-3 (154 to 352 residues) (unknown origin) fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 3.20nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 3.20nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 3.20nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 3.40nMAssay Description:Binding affinity to human N-terminal His-tagged cIAP1 BIR2-3 C202A/C213G mutant after 60 mins by HTRF assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 3.40nMAssay Description:Binding affinity to human N-terminal His-tagged cIAP1 BIR2-3 C202A/C213G mutant after 60 mins by HTRF assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 3.60nMAssay Description:Binding affinity to human N-terminal His-tagged cIAP1 BIR2-3 C202A/C213G mutant after 60 mins by HTRF assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 3.70nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Binding affinity to human N-terminal His-tagged cIAP1 BIR2-3 C202A/C213G mutant after 60 mins by HTRF assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 4.20nMAssay Description:Binding affinity to human N-terminal His-tagged cIAP1 BIR2-3 C202A/C213G mutant after 60 mins by HTRF assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 4.5nMAssay Description:Binding affinity to human N-terminal His-tagged cIAP1 BIR2-3 C202A/C213G mutant after 60 mins by HTRF assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 4.5nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 4.70nMAssay Description:Binding affinity to human N-terminal His-tagged cIAP1 BIR2-3 C202A/C213G mutant after 60 mins by HTRF assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 4.80nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 4.80nMAssay Description:Binding affinity to human N-terminal His-tagged cIAP1 BIR2-3 C202A/C213G mutant after 60 mins by HTRF assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 4.90nMAssay Description:Binding affinity to human N-terminal His-tagged cIAP1 BIR2-3 C202A/C213G mutant after 60 mins by HTRF assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of cIAP1 BIR2-3 (154 to 352 residues) (unknown origin) fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 5.60nMAssay Description:Binding affinity to human N-terminal His-tagged cIAP1 BIR2-3 C202A/C213G mutant after 60 mins by HTRF assayMore data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 6.40nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of cIAP1 BIR2-3 (154 to 352 residues) (unknown origin) fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of human ErbB2More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of human ErbB2More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of human EGFR expressed in SF9 cellsMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of cIAP1 BIR3 (154 to 352 residues) (unknown origin) by fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of human ErbB2More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of human EGFR expressed in SF9 cellsMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 8nMpH: 8.0 T: 2°CAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Bristol-Myers Squibb Research
Curated by ChEMBL
Bristol-Myers Squibb Research
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of XIAP BIR2-3 (125 to 356 residues) C202A/C213G mutant (unknown origin) fluoresceinated dimeric SMAC peptide based fluorescence polarizat...More data for this Ligand-Target Pair